FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1045121760> ?p ?o ?g. }

• W1045121760 endingPage "439" @default.
• W1045121760 startingPage "434" @default.
• W1045121760 abstract "To assess the efficacy of neoadjuvant systemic therapy (NST) at increasing the rate of successful breast-conserving therapy (BCT) in triple negative breast cancer.Inducing tumor regression to permit BCT is often cited to support administration of NST. To quantify this benefit, we conducted a surgical companion study to CALGB40603, a randomized phase II, 2×2 factorial trial of neoadjuvant paclitaxel ± carboplatin ± bevacizumab (B) followed by doxorubicin plus cyclophosphamide ± B in stage II-III triple negative breast cancer.Before and after NST, treating surgeons evaluated BCT candidacy by clinico-radiographic criteria; surgery performed was at surgeon and patient discretion. We measured (1) conversion rates from BCT-ineligible to BCT-eligible, (2) surgical choices in BCT candidates, and (3) rates of successful BCT with tumor-free margins.Four hundred four patients were assessable for surgical outcomes. Two hundred nineteen (54%) were BCT candidates before NST. One hundred ninety-seven (90%) remained BCT candidates after NST, of whom 138 (70%) chose BCT, which was successful in 130 (94%). Of 185 (46%) who were not BCT candidates before NST, 78 (42%) converted to candidates with NST. Of these, 53 (68%) chose BCT with a 91% (48/53) success rate. The overall BCT-eligibility rate rose from 54% to 68% (275/404) with NST. Addition of carboplatin, B, or both increased conversion rates.This is the first study to document prospectively a 42% conversion rate from BCT-ineligible to BCT-eligible, resulting in a 14% absolute increase in BCT eligibility. BCT was successful in 93% of patients who opted for it, but 31% of BCT-eligible patients still chose mastectomy." @default.
• W1045121760 created "2016-06-24" @default.
• W1045121760 creator A5001268619 @default.
• W1045121760 creator A5012965017 @default.
• W1045121760 creator A5016516852 @default.
• W1045121760 creator A5023917993 @default.
• W1045121760 creator A5045617170 @default.
• W1045121760 creator A5047713528 @default.
• W1045121760 creator A5057763165 @default.
• W1045121760 creator A5058115979 @default.
• W1045121760 creator A5070245248 @default.
• W1045121760 creator A5073571977 @default.
• W1045121760 date "2015-09-01" @default.
• W1045121760 modified "2023-10-06" @default.
• W1045121760 title "Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates" @default.
• W1045121760 cites W1551111627 @default.
• W1045121760 cites W1967076728 @default.
• W1045121760 cites W2009199535 @default.
• W1045121760 cites W2030196743 @default.
• W1045121760 cites W2032173242 @default.
• W1045121760 cites W2050310681 @default.
• W1045121760 cites W2051191349 @default.
• W1045121760 cites W2086064725 @default.
• W1045121760 cites W2087179076 @default.
• W1045121760 cites W2096602429 @default.
• W1045121760 cites W2096745115 @default.
• W1045121760 cites W2118605519 @default.
• W1045121760 cites W2122133674 @default.
• W1045121760 cites W2129695292 @default.
• W1045121760 cites W2131915049 @default.
• W1045121760 cites W2133959685 @default.
• W1045121760 cites W2134540394 @default.
• W1045121760 cites W2171958606 @default.
• W1045121760 cites W4245606248 @default.
• W1045121760 doi "https://doi.org/10.1097/sla.0000000000001417" @default.
• W1045121760 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4710511" @default.
• W1045121760 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26222764" @default.
• W1045121760 hasPublicationYear "2015" @default.
• W1045121760 type Work @default.
• W1045121760 sameAs 1045121760 @default.
• W1045121760 citedByCount "145" @default.
• W1045121760 countsByYear W10451217602015 @default.
• W1045121760 countsByYear W10451217602016 @default.
• W1045121760 countsByYear W10451217602017 @default.
• W1045121760 countsByYear W10451217602018 @default.
• W1045121760 countsByYear W10451217602019 @default.
• W1045121760 countsByYear W10451217602020 @default.
• W1045121760 countsByYear W10451217602021 @default.
• W1045121760 countsByYear W10451217602022 @default.
• W1045121760 countsByYear W10451217602023 @default.
• W1045121760 crossrefType "journal-article" @default.
• W1045121760 hasAuthorship W1045121760A5001268619 @default.
• W1045121760 hasAuthorship W1045121760A5012965017 @default.
• W1045121760 hasAuthorship W1045121760A5016516852 @default.
• W1045121760 hasAuthorship W1045121760A5023917993 @default.
• W1045121760 hasAuthorship W1045121760A5045617170 @default.
• W1045121760 hasAuthorship W1045121760A5047713528 @default.
• W1045121760 hasAuthorship W1045121760A5057763165 @default.
• W1045121760 hasAuthorship W1045121760A5058115979 @default.
• W1045121760 hasAuthorship W1045121760A5070245248 @default.
• W1045121760 hasAuthorship W1045121760A5073571977 @default.
• W1045121760 hasBestOaLocation W10451217602 @default.
• W1045121760 hasConcept C121608353 @default.
• W1045121760 hasConcept C126322002 @default.
• W1045121760 hasConcept C141071460 @default.
• W1045121760 hasConcept C146357865 @default.
• W1045121760 hasConcept C151730666 @default.
• W1045121760 hasConcept C2776694085 @default.
• W1045121760 hasConcept C2777757722 @default.
• W1045121760 hasConcept C2778239845 @default.
• W1045121760 hasConcept C2778292576 @default.
• W1045121760 hasConcept C2781451048 @default.
• W1045121760 hasConcept C530470458 @default.
• W1045121760 hasConcept C71924100 @default.
• W1045121760 hasConcept C86803240 @default.
• W1045121760 hasConceptScore W1045121760C121608353 @default.
• W1045121760 hasConceptScore W1045121760C126322002 @default.
• W1045121760 hasConceptScore W1045121760C141071460 @default.
• W1045121760 hasConceptScore W1045121760C146357865 @default.
• W1045121760 hasConceptScore W1045121760C151730666 @default.
• W1045121760 hasConceptScore W1045121760C2776694085 @default.
• W1045121760 hasConceptScore W1045121760C2777757722 @default.
• W1045121760 hasConceptScore W1045121760C2778239845 @default.
• W1045121760 hasConceptScore W1045121760C2778292576 @default.
• W1045121760 hasConceptScore W1045121760C2781451048 @default.
• W1045121760 hasConceptScore W1045121760C530470458 @default.
• W1045121760 hasConceptScore W1045121760C71924100 @default.
• W1045121760 hasConceptScore W1045121760C86803240 @default.
• W1045121760 hasIssue "3" @default.
• W1045121760 hasLocation W10451217601 @default.
• W1045121760 hasLocation W10451217602 @default.
• W1045121760 hasLocation W10451217603 @default.
• W1045121760 hasLocation W10451217604 @default.
• W1045121760 hasOpenAccess W1045121760 @default.
• W1045121760 hasPrimaryLocation W10451217601 @default.
• W1045121760 hasRelatedWork W1255356622 @default.
• W1045121760 hasRelatedWork W167319750 @default.
• W1045121760 hasRelatedWork W2367105124 @default.

• next